| Literature DB >> 34239581 |
Fozia Amin1, Baharullah Khattak1, Amal Alotaibi2, Muhammad Qasim1, Ijaz Ahmad3, Riaz Ullah4, Mohammed Bourhia5, Anadil Gul6, Saira Zahoor7, Rizwan Ahmad8.
Abstract
The development of green technology is creating great interest for researchers towards low-cost and environmentally friendly methods for the synthesis of nanoparticles. Copper oxide nanoparticles (CuO-NPs) attracted many researchers due to their electric, catalytic, optical, textile, photonic, monofluid, and pharmacological activities that depend on the shape and size of the nanoparticles. This investigation aims copper oxide nanoparticles synthesis using Aerva javanica plant leaf extract. Characterization of copper oxide nanoparticles synthesized by green route was performed by three different techniques: X-Ray Diffraction (XRD), Fourier Transform Infrared (FTIR) Spectroscopy, and Scanning Electron Microscopy (SEM). X-ray diffraction (XRD) reveals the crystalline morphology of CuO-NPs and the average crystal size obtained is 15 nm. SEM images showed the spherical nature of the particles and size is lying in the 15-23 nm range. FTIR analysis confirms the functional groups of active components present in the extract which are responsible for reducing and capping agents for the synthesis of CuO-NPs. The synthesized CuO-NPs were studied for their antimicrobial potential against different bacterial as well as fungal pathogens. The results indicated that CuO-NPs show maximum antimicrobial activities against all the selected bacterial and fungal pathogens. Antimicrobial activities of copper oxide nanoparticles were compared with standard drugs Norfloxacin and amphotericin B antibiotics. Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of copper oxide nanoparticles were 128 μg/mL against all selected bacterial pathogens. MIC of fungus and minimum fungicidal concentration (MFC) of CuO-NPs were 160 μg/mL. Thus, CuO-NPs can be utilized as a broad-spectrum antimicrobial agent. The cytotoxic activity of the synthesized CuO-NPs suggested that toxicity was negligible at concentrations below 60 μg/mL.Entities:
Year: 2021 PMID: 34239581 PMCID: PMC8235967 DOI: 10.1155/2021/5589703
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1XRD patterns of copper oxide nanoparticles (CuO-NPs).
Figure 2SEM micrograph of copper oxide nanoparticles.
Figure 3FTIR analysis of copper oxide nanoparticles.
Figure 4Antibacterial activity of CuO-NPs against all selected bacterial pathogens at a concentration of 50 ug/ml: (a) E. coli. (b) P. aeruginosa. (c) A. baumannii. (d) S. aureus.
Different inhibition zone of CuO-NPs against selected bacterial strains.
| — | Inhibition of zone (mm) against fungal strains | |||
|---|---|---|---|---|
| — |
|
|
|
|
| CuO-NPs | 5 ± 1 | 5 ± 1 | 9 ± 1 | 5 ± 1 |
|
| 2 ± 1 | 0 | 0 | 0 |
| Norfloxacin | 12 ± 0 | 5 ± 0 | 4 ± 0 | 3 ± 1 |
| DMSO | 0 | 0 | 0 | 0 |
Norfloxacin as a positive control; DMSO = dimethyl sulfoxide as negative control; ± standard error mean.
Figure 5Antibacterial activity of copper oxide nanoparticle against selected bacterial strains at a concentration of 100 μg/ml: (a) E. coli. (b) P. aeruginosa. (c) Acinetobacter. (d) S. aureus.
Different zone of inhibition of CuO-NPs against selected bacterial strains.
| — | Inhibition zone (mm) against fungal strains | |||
|---|---|---|---|---|
| — |
|
|
|
|
| CuO-NPs | 6 ± 1 | 10 ± 1 | 12 ± 1 | 12 ± 1 |
|
| 4 ± 1 | 3 ± 1 | 3 ± 1 | 2 ± 0.25 |
| Norfloxacin | 14 ± 1 | 5 ± 0 | 5 ± 0 | 5 ± 1 |
| DMSO | 0 | 0 | 0 | 0 |
Norfloxacin as a positive control; DMSO = dimethyl sulfoxide as negative control; ± standard error mean.
Figure 6Antibacterial activity of CuO-NPs against selected bacterial strains at a concentration of 200 μg/ml: (a) E. coli. (b) P. aeruginosa. (c) S. aureus. (d) Acinetobacter.
Different inhibition zones of all samples against selected bacterial strains.
| — | Inhibition zone (mm) against fungal strains | |||
|---|---|---|---|---|
| — |
|
|
|
|
| CuO-NPs | 7 ± 0.57 | 13 ± 1 | 12 ± 1 | 12 ± 1 |
|
| 5 ± 0.35 | 4 ± 0 | 5 ± 0.35 | 4 ± 0 |
| Norfloxacin | 15 ± 1 | 5 ± 0 | 5 ± 1 | 6 ± 0 |
| DMSO | 0 | 0 | 0 | 0 |
Norfloxacin as a positive control; DMSO = dimethyl sulfoxide as negative control; ± standard error mean.
Figure 7Antifungal activity of CuO-NPs against selected fungus pathogens at a concentration of 100 μg/ml: (a) C. albicans. (b) C. krusei. (c) C. tropicalis. (d) C. albicans.
Different inhibition zones of all samples fungal pathogens Candida albicans.
| — | Inhibition zone (mm) against fungal strains | |||
|---|---|---|---|---|
| — |
|
|
|
|
| CuO-NPs | 9 + 0.5 | 5 + 1 | 4 + 0 | 7 + 1 |
|
| 0 | 0 | 3 + 0 | 3 + 0.5 |
| Amphotericin B | 4 + 1 | 3 + 0 | 3 + 1 | 3 + 0 |
| DMSO | 0 | 0 | 0 | 0 |
MIC and MBC determination of coppe oxide nanoparticles.
| Bacterial strains | Concentrations | |||||
|---|---|---|---|---|---|---|
| 256 | 128 | 46 | 32 | 16 | 8 | |
|
| − | − | + | + | + | + |
|
| − | − | − | + | + | + |
|
| − | − | + | + | + | + |
|
| − | − | − | + | + | + |
Positive (+) = growth; negative (−) = no growth.
MIC and MFC determination of copper oxide nanoparticles.
| Fungal strains | Concentrations | |||||
|---|---|---|---|---|---|---|
| 320 | 160 | 80 | 40 | 20 | 10 | |
|
| − | − | + | + | + | + |
|
| − | − | + | + | + | + |
|
| − | − | + | + | + | + |
|
| − | − | + | + | + | + |
Positive (+) = growth; negative (−) = no growth.
MTT assay results of synthesized CuO-NPs at 550°C.
| S. no. | Concentration | Cell visibility (%) |
|---|---|---|
| 1 | 0 | 100 |
| 2 | 600 | 35 |
| 3 | 300 | 37 |
| 4 | 150 | 44 |
| 5 | 125 | 45 |
| 6 | 100 | 60 |
| 7 | 70 | 60 |
| 8 | 60 | 80 |
| 9 | 50 | 80 |
| 10 | 30 | 80 |
| 11 | 10 | 80 |